The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice

Miyuki Abe, Megumi Funakoshi-Tago, Kenji Tago, Jun Kamishimoto, Eriko Aizu-Yokota, Yoshiko Sonoda, Tadashi Kasahara

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)

Abstract

The somatic Jak2 mutation (V617F) was identified in most patients with polycythemia vera (PV). Here, we show that the activating Jak2 V617F mutant completely protected Ba/F3 cells from cytokine withdrawal-induced apoptotic cell death. Interestingly, Ba/F3 cells expressing Jak2 V617F mutant induced rapid tumorigenesis in nude mice, leading to rapid death. Whereas an injection of Ba/F3 cells expressing wild-type Jak2 had no effect, an injection of Ba/F3 cells expressing Jak2 V617F mutant promptly invaded and spread into various distinct organs, such as the liver and spleen. Strikingly, Jak2 inhibitor, AG490 potently inhibited cytokine-independent cell growth induced by the Jak2 V617F mutant. Also, treatment with AG490 effectively delayed Jak2 V617F mutant-induced tumorigenesis in nude mice. Thus, our results both in vitro and in vivo suggest that Jak2 harboring V617F mutation is a potent oncogene able to promote cell transformation and tumorigenesis.

Original languageEnglish
Pages (from-to)870-877
Number of pages8
JournalInternational Immunopharmacology
Volume9
Issue number7-8
DOIs
Publication statusPublished - 2009 Jul 1

Keywords

  • Anti-apoptosis
  • Jak2
  • Polycythemia vera (PV)
  • Tumorigenesis
  • V617F

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Fingerprint Dive into the research topics of 'The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice'. Together they form a unique fingerprint.

Cite this